Long-term bisphosphonate in breast cancer ‘provides no extra benefit’
It may be time to question the role of the bone-sparing therapy, say expert commentators.
Extending zoledronate treatment beyond two years after adjuvant chemotherapy does not improve the prognosis of high-risk patients with early breast cancer, clinical trial results show.
In the multicentre phase 3 open-label SUCCESS A trial, German researchers enrolled patients with either node-positive or high-risk node-negative primary invasive breast cancer from 2005-2007, with the last participant completing the trial in 2014.
